Aliases & Classifications for Urticaria

MalaCards integrated aliases for Urticaria:

Name: Urticaria 12 77 30 56 6 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1555
ICD9CM 36 708.8
MeSH 45 D014581
ICD10 34 L50

Summaries for Urticaria

Disease Ontology : 12 A skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located in the upper dermis.

MalaCards based summary : Urticaria is related to physical urticaria and cold urticaria, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Urticaria is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and NF-kappaB Signaling. The drugs Clarinex and Levocetirizine have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and thyroid, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Hives, also known as urticaria, is a kind of skin rash with red, raised, itchy bumps. They may also burn... more...

Related Diseases for Urticaria

Diseases related to Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 395)
# Related Disease Score Top Affiliating Genes
1 physical urticaria 34.2 ADGRE2 FCER1A
2 cold urticaria 34.1 CMA1 NLRP3 PLCG2 RNASE3
3 angioedema 31.0 C1S CPN1 F12 HNMT LTC4S PTGS1
4 rhinitis 30.8 HRH1 IGHE RNASE3
5 allergic rhinitis 30.5 HRH1 IGHE RNASE3
6 toxocariasis 30.2 IGHE RNASE3
7 latex allergy 29.9 IGHE RNASE3
8 conjunctivitis 29.7 HRH1 NLRP3 RNASE3
9 allergic hypersensitivity disease 29.7 FCER2 HRH1 IGHE RNASE3 TPT1
10 dermatitis, atopic 29.6 CMA1 FCER2 HRH1 IGHE RNASE3 SELE
11 asthma 28.6 FCER1A FCER2 HNMT HRH1 IGHE LTC4S
12 vibratory urticaria 12.7
13 cholinergic urticaria 12.6
14 solar urticaria 12.5
15 allergic urticaria 12.5
16 urticaria, aquagenic 12.5
17 papular urticaria 12.4
18 familial cold autoinflammatory syndrome 3 12.2
19 schnitzler syndrome 12.2
20 mastocytosis, cutaneous 12.2
21 muckle-wells syndrome 12.2
22 familial cold autoinflammatory syndrome 1 12.2
23 nodular urticaria pigmentosa 12.1
24 dermatographia 12.1
25 urticaria, familial localized heat 12.0
26 plaque-form urticaria pigmentosa 12.0
27 typical urticaria pigmentosa 12.0
28 familial cold autoinflammatory syndrome 11.8
29 dermographism, familial 11.7
30 familial cold autoinflammatory syndrome 4 11.3
31 exercise-induced anaphylaxis 11.3
32 cryopyrin-associated periodic syndrome 11.3
33 fascioliasis 11.1
34 hypersensitivity vasculitis 11.1
35 arthus reaction 11.0
36 carboxypeptidase n deficiency 10.9
37 netherton syndrome 10.9
38 familial cold autoinflammatory syndrome 2 10.9
39 deafness, autosomal dominant 34, with or without inflammation 10.9
40 paragonimiasis 10.9
41 cystic echinococcosis 10.9
42 anca-associated vasculitis 10.9
43 cutaneous mastocytoma 10.9
44 distomatosis 10.9
45 episodic angioedema with eosinophilia 10.9
46 hypocomplementemic urticarial vasculitis 10.9
47 monoclonal mast cell activation syndrome 10.9
48 erythema multiforme 10.6
49 dermatitis 10.6
50 mastocytosis 10.5

Comorbidity relations with Urticaria via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential
Ischemic Heart Disease

Graphical network of the top 20 diseases related to Urticaria:



Diseases related to Urticaria

Symptoms & Phenotypes for Urticaria

UMLS symptoms related to Urticaria:


nausea and vomiting, constipation, fever, fatigue, abdominal pain, edema, pruritus, pain, chest pain, diarrhea, headache, syncope, chronic pain, sciatica, icterus, exanthema, coughing, vertigo/dizziness, dyspepsia, heartburn, gastrointestinal gas, symptoms, halitosis, pelvic pain, welts, darier's sign

MGI Mouse Phenotypes related to Urticaria:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 CMA1 FCER1A FCER2 HRH1 NLRP3 PLCG2
2 immune system MP:0005387 9.36 CMA1 CPN1 FCER1A FCER2 HRH1 LTC4S

Drugs & Therapeutics for Urticaria

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Clarinex 19 DESLORATADINE Schering-Plough February 2002

Drugs for Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 456)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levocetirizine Approved Phase 4,Phase 3,Phase 1,Phase 2 130018-77-8 1549000
2
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83881-51-0 2678
3
Desloratadine Approved, Investigational Phase 4,Phase 3,Phase 2 100643-71-8 124087
4
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6 774
5
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
6
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 242138-07-4
7
Hydroxyzine Approved Phase 4 68-88-2 3658
8
Fexofenadine Approved, Investigational Phase 4,Phase 2 83799-24-0 3348
9
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
10
Loratadine Approved, Investigational Phase 4,Phase 3,Phase 2 79794-75-5 3957
11
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
12
Cefazolin Approved Phase 4,Not Applicable 25953-19-9 656510 33255
13
Clevidipine Approved, Investigational Phase 4 167221-71-8
14
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 22916-47-8 4189
15
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
16
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
17
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
18
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
19
Azelastine Approved Phase 4,Phase 3 58581-89-8 2267
20
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
21
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
22
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
23
Icatibant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130308-48-4, 138614-30-9 71364
24
Zinc Approved, Investigational Phase 4 7440-66-6 32051
25
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
26
Tranexamic Acid Approved Phase 4,Phase 3 1197-18-8 5526
27 Benralizumab Approved, Investigational Phase 4 1044511-01-4
28
Dapsone Approved, Investigational Phase 4 80-08-0 2955
29
Tofacitinib Approved, Investigational Phase 4 477600-75-2
30
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
31
Menthol Approved Phase 4 2216-51-5 16666
32
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 7440-70-2 271
33
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 50-14-6 5280793
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 1406-16-2
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
36
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
37
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
38
Bradykinin Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-82-2 439201
39
Lactitol Investigational Phase 4,Phase 2 585-86-4, 585-88-6 493591
40
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-74-1 65513
41 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2
47 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1
50 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 540)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria Unknown status NCT00346606 Phase 4 Denosin® and Xyzal®
2 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
3 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
4 Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Completed NCT01250652 Phase 4 Levocetirizine;Levocetirizine plus Hydroxyzine
5 Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria Completed NCT01940393 Phase 4 Cetirizine;Desloratadine;Fexofenadine;Ebastine;Bilastine
6 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Completed NCT02392624 Phase 4 Omalizumab;Placebo
7 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4 Desloratadine
8 A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions Completed NCT00600847 Phase 4 desloratadine;desloratadine;placebo
9 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Completed NCT01701583 Phase 4 Omalizumab
10 Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) Completed NCT00536380 Phase 4 5-mg Desloratadine;10-mg Desloratadine;20-mg Desloratadine
11 CUTE (Chronic Urticaria Treatment Evaluation) Completed NCT00264303 Phase 4 Levocetirizine;Desloratadine
12 A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) Completed NCT00783354 Phase 4 desloratadine;desloratadine
13 An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540) Completed NCT00795522 Phase 4 Desloratadine
14 A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) Completed NCT00751218 Phase 4 desloratadine;placebo;cetirizine
15 Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Completed NCT02576041 Phase 4 Bilastine;Placebo
16 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal
17 Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Completed NCT01121458 Phase 4 Clevidipine
18 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China Completed NCT02336178 Phase 4 Benefix
19 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Completed NCT01567865 Phase 4
20 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
21 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
22 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
23 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
24 Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease Completed NCT00549601 Phase 4 Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day);Rivastigmine patch (9.5 mg/day);Rivastigmine capsules (6 mg to 12 mg/day)
25 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
26 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed NCT01880840 Phase 4 205.5 mcg of azelastine hydrochloride;137 mcg of azelastine hydrochloride
27 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
28 RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain Completed NCT02043704 Phase 4 IV Acetaminophen
29 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
30 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
31 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
32 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
33 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
34 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety Completed NCT00359801 Phase 4 Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care;Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
35 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Recruiting NCT03111628 Phase 4 Omalizumab
36 Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody Recruiting NCT03183024 Phase 4
37 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
38 Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Recruiting NCT03016884 Phase 4
39 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
40 Safety of Rabivax-S for Pre-exposure Prophylaxis Enrolling by invitation NCT03741270 Phase 4
41 Tranexamic Acid and Spontaneous Chronic Urticaria Not yet recruiting NCT03789422 Phase 4 association of levocetirizine and tranexamic acid;Levocetirizine only
42 Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery Not yet recruiting NCT03460509 Phase 4 Sugammadex
43 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
44 A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736) Terminated NCT00751166 Phase 4 Desloratadine;Cetirizine;placebo
45 A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
46 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4 icatibant
47 Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation Withdrawn NCT02742805 Phase 4 Omalizumab
48 Ceftaroline in the Treatment of Bone and Joint Infections Withdrawn NCT02005068 Phase 4 Ceftaroline
49 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
50 High Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria Unknown status NCT02873364 Phase 3 Vitamin D3 (High dose);Vitamin D3 (Low dose)

Search NIH Clinical Center for Urticaria

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: urticaria

Genetic Tests for Urticaria

Genetic tests related to Urticaria:

# Genetic test Affiliating Genes
1 Urticaria 30

Anatomical Context for Urticaria

MalaCards organs/tissues related to Urticaria:

42
Skin, Testes, Thyroid, Bone, Neutrophil, T Cells, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Urticaria:

20
The Upper Dermis

Publications for Urticaria

Articles related to Urticaria:

(show top 50) (show all 4059)
# Title Authors Year
1
Chronic spontaneous urticaria associated with colon adenocarcinoma: A paraneoplastic manifestation? A case report and review of literature. ( 30581946 )
2019
2
Trends in hospitalizations related to anaphylaxis, angioedema and urticaria in the United States. ( 30769181 )
2019
3
Does angioedema influence the quality of life in chronic spontaneous urticaria patients? ( 30769182 )
2019
4
Chronic spontaneous urticaria and angioedema requiring treatment with omalizumab in a patient with hereditary angioedema. ( 30831259 )
2019
5
Higher Levels of Depression and Anxiety in Patients with Chronic Urticaria. ( 30609422 )
2019
6
Efficacy and safety of omalizumab (Xolair®) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial. ( 30654196 )
2019
7
Exercise-induce anaphylaxis, food-dependent exercise-induce anaphylaxis, cholinergic urticaria and Kounis syndrome. ( 30774109 )
2019
8
H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria. ( 30708143 )
2019
9
Treatments of Cold Urticaria: A Systematic Review. ( 30776418 )
2019
10
Headache deteriorates the quality of life in children with chronic spontaneous urticaria. ( 30686612 )
2019
11
Cellular and Humoral Responses to Cte f 2, a Cat Flea Allergen, in Children with Papular Urticaria. ( 30904917 )
2019
12
Patient experiences of using Chinese herbal medicine for psoriasis vulgaris and chronic urticaria: A qualitative study. ( 30897010 )
2019
13
Urticaria pigmentosa-like skin disease in a domestic shorthair cat. ( 30671254 )
2019
14
Advances in the pathogenesis representing definite outcomes in chronic urticaria. ( 30676342 )
2019
15
Relevance of the basophil high-affinity IgE receptor in chronic urticaria: Clinical experience from a tertiary care institution. ( 30685572 )
2019
16
Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study). ( 30704532 )
2019
17
Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine. ( 30717573 )
2019
18
The response to treatment in chronic spontaneous urticaria depends on how it is measured. ( 30731179 )
2019
19
The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience. ( 30745975 )
2019
20
The role of patient-reported outcomes in the management of chronic spontaneous urticaria. ( 30746981 )
2019
21
Biologic-induced urticaria due to polysorbate 20. ( 30758866 )
2019
22
Bloodletting therapy for treating patients with chronic urticaria: A systematic review and meta-analysis protocol. ( 30762796 )
2019
23
Higher mean platelet volume is associated with paediatric chronic spontaneous urticaria and with a more severe disease in the affected children. ( 30790277 )
2019
24
Basophil count is a sensitive marker for clinical progression in a chronic spontaneous urticaria patient treated with omalizumab. ( 30792119 )
2019
25
Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. ( 30793986 )
2019
26
Characterization of chronic urticaria and associated conditions in a large population of adolescents. ( 30797847 )
2019
27
Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment. ( 30801715 )
2019
28
Differentiation between control subjects and patients with chronic spontaneous urticaria based on the ability of anti-IgE autoantibodies (AAbs) to induce FcεRI crosslinking, as compared to anti-FcεRIα AAbs. ( 30803853 )
2019
29
On the Lipophilic Nature of Autoreactive IgE in Chronic Spontaneous Urticaria. ( 30809311 )
2019
30
Serum miR-125a-5p and CCL17 Upregulated in Chronic Spontaneous Urticaria and Correlated with Treatment Response. ( 30809682 )
2019
31
Factors associated with relapses among patients treated for acute urticaria. ( 30816579 )
2019
32
Contact urticaria due to phenoxyethanol in ultrasound gel. ( 30820971 )
2019
33
Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: A retrospective cohort study. ( 30821591 )
2019
34
Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria. ( 30823944 )
2019
35
The burden of chronic urticaria: French baseline data from the international real-life AWARE study. ( 30827942 )
2019
36
Real-life experience in the treatment of solar urticaria: retrospective cohort study. ( 30828851 )
2019
37
"Pink Sign": The Importance of Short-Term Occlusive Testing in Suspected Cases of Contact Urticaria. ( 30829798 )
2019
38
Follicular Traction Urticaria: An Occult Case Diagnosed by Patch Testing and Review of the Literature. ( 30829807 )
2019
39
Chronic urticaria and drug hypersensitivity in children. ( 30830063 )
2019
40
Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study. ( 30835579 )
2019
41
Does omalizumab treatment affect serum dehydroepiandrosterone sulphate levels in chronic idiopathic urticaria? ( 30858786 )
2019
42
Prevalence Estimates For Chronic Urticaria in the United States: a gender and age adjusted population analysis. ( 30872154 )
2019
43
Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria. ( 30879003 )
2019
44
A Sea Change in the Treatment of Chronic Urticaria. ( 30879603 )
2019
45
Strongyloides infection as a reversible cause of chronic urticaria. ( 30881049 )
2019
46
Chronic Urticaria in the Real-Life Clinical Practice Setting in Portugal: Baseline Results from the Non-Interventional Multicentre AWARE Study. ( 30896394 )
2019
47
Predictive factors for progression to chronicity or recurrence after the first attack of acute urticaria in preschool-age children. ( 30904182 )
2019
48
Sexual Intercourse as a Trigger of Inducible Urticaria. ( 30904579 )
2019
49
Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: A systematic review and meta-analysis. ( 30906452 )
2019
50
Tumor necrosis factor-alpha and Fas/Fas ligand signaling pathways in chronic spontaneous urticaria. ( 30911316 )
2019

Variations for Urticaria

ClinVar genetic disease variations for Urticaria:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh38 Chromosome 5, 177404231: 177404231
3 MEFV NM_000243.2(MEFV): c.2084A> G (p.Lys695Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs104895094 GRCh37 Chromosome 16, 3293403: 3293403
4 MEFV NM_000243.2(MEFV): c.2084A> G (p.Lys695Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs104895094 GRCh38 Chromosome 16, 3243403: 3243403

Expression for Urticaria

Search GEO for disease gene expression data for Urticaria.

Pathways for Urticaria

GO Terms for Urticaria

Cellular components related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 AOC1 C1S CMA1 CPN1 F12 RNASE3
2 extracellular region GO:0005576 9.28 AOC1 C1S CMA1 CPN1 F12 FCER2

Biological processes related to Urticaria according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.77 C1S F12 IGHE NLRP3 RNASE3
2 Fc-epsilon receptor signaling pathway GO:0038095 9.63 FCER1A IGHE PLCG2
3 positive regulation of receptor internalization GO:0002092 9.51 PLCG2 SELE
4 cellular oxidant detoxification GO:0098869 9.5 LTC4S PTGS1 PTGS2
5 long-chain fatty acid biosynthetic process GO:0042759 9.49 LTC4S PTGS2
6 prostaglandin metabolic process GO:0006693 9.48 PTGS1 PTGS2
7 prostaglandin biosynthetic process GO:0001516 9.43 PTGS1 PTGS2
8 inflammatory response GO:0006954 9.43 ADGRE2 HRH1 NLRP3 PTGS1 PTGS2 SELE
9 peptide metabolic process GO:0006518 9.4 CMA1 CPN1
10 cyclooxygenase pathway GO:0019371 9.26 PTGS1 PTGS2
11 cellular response to histamine GO:0071420 9.16 AOC1 HRH1
12 regulation of inflammatory response GO:0050727 8.92 CMA1 NLRP3 PTGS2 SELE

Molecular functions related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.55 ADGRE2 AOC1 C1S F12 TPT1
2 IgE binding GO:0019863 8.96 FCER1A FCER2
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Urticaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....